What is in it for my patient? Moving beyond short-term benefits and risks for recently approved DMTs in MS
Agenda
Join Prof. Gavin Giovannoni, Prof. David Baker and Prof. Sonia Batista for the next interactive multiple sclerosis seminar of Janssen’s Neuroscience Medical Education (NSME) Forum. Here, the faculty will reflect on the therapeutic potential of new disease-modifying therapies (DMTs) for MS and discuss based on clinical scenarios what it means for patients in practice. This is a unique opportunity to meet and communicate with the experts, share your ideas and experiences and get your questions answered.
Please note that this programme has been submitted to the European Accreditation Committee in CNS (EACIC) for accreditation.
Agenda
Time (CET) | Session | Speaker(s) |
18:30 | Welcome and introduction | Prof. Gavin Giovannoni |
18:32 | Mode of action: Similarities and differences between new DMTs | Prof. David Baker |
18:40 | Clinical trial data of new DMTs | Prof. Sonia Batista |
18:48 | Practical application of new DMTs: Discussion based on clinical scenarios |
All faculty
Chair: Prof. Gavin Giovannoni |
19:28 | Final concluding statements | Prof. Gavin Giovannoni |
Learning objectives
After this webinar, participants should be able to:
- Compare the different characteristics of DMTs approved in the past 1–2 years
- Reflect on the potential benefits of these new DMTs for different patient groups
- Discuss how newly approved DMTs may have an impact on long-term strategies of disease management
- Analyse how newly approved DMTs will affect healthcare resource utilisation
Faculty:
- Prof. Gavin Giovannoni, UK
- Prof. David Baker, UK
- Prof. Sonia Batista, Portugal
More Info
1 Hours
EM-72360 - Date of preparation: September 2021